TICKVALE
>⌘K
Nasdaq · CIK 0001232524 · PHARMACEUTICAL PREPARATIONS

Jazz Pharmaceuticals plc

JAZZ chart by TradingView
P/E 17.8xP/B 3.5xP/SALES 3.6xEV/EBITDA 20.2xFCF YIELD 9.52%

PRICE HISTORY

LIVE · NASDAQ
JAZZ chart by TradingView
REVENUE FY2025 ENDED DEC 2025
$4.3B
EBITDA
$-0.4B
FREE CASH FLOW
$1.3B
EPS
$-5.84
GROSS MARGIN
ROIC
-4.30%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET

VALUATION

what you pay for a unit of the business7 CHARTS

P / E RATIO (TTM)

17.8x
-14%
LATEST · Q2 FY26
17.8xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
12.1x424.3x

P / SALES (TTM)

3.6x
-31%
LATEST · Q2 FY26
3.6xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
1.6x6.2x

P / BOOK

3.5x
-15%
LATEST · Q2 FY26
3.5xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
1.7x4.5x

EV / EBITDA (TTM)

20.2x
+18%
LATEST · Q2 FY26
20.2xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
11.7x782.3x

EV / REVENUE (TTM)

4.2x
-35%
LATEST · Q2 FY26
4.2xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
2.6x7.1x

FCF YIELD (TTM)

9.52%
+2.6pp
LATEST · Q2 FY26
9.52%Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
6.26%19.98%

DIVIDEND YIELD (TTM)

LATEST · Q2 FY26
Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

GROWTH

is the business getting bigger5 CHARTS

REVENUE

$1.2B
+223%
LATEST · Q2 FY26
1.2BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

EBITDA (DERIVED)

$0.4B
+157%
LATEST · Q2 FY26
0.4BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

NET INCOME

$0.2B
+115%
LATEST · Q2 FY26
0.2BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

EPS (DILUTED)

$2.78
+91%
LATEST · Q2 FY26
2.78Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

REVENUE GROWTH YOY

15.55%
+5.8pp
LATEST · Q2 FY26
15.55%Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
-0.46%39.48%

PROFITABILITY & RETURNS

what survives to the bottom, and what it earns on capital4 CHARTS

FCF MARGIN

32.91%
-2.0pp
LATEST · Q2 FY26
32.91%Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
4.59%60.71%

RETURN ON CAPITAL

12.49%
+2.5pp
LATEST · Q2 FY26
12.49%Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
-5.14%16.62%

RETURN ON EQUITY (TTM)

19.59%
-0.2pp
LATEST · Q2 FY26
19.59%Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
-12.47%21.98%

MARGIN FUNNEL

every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the business
GROSS MARGIN
OPERATING MARGIN20.54%
NET MARGIN15.96%
FCF MARGIN32.91%
73.6534.82-4.00-42.83-81.65OPERNETFCFQ3 FY16Q3 FY17Q3 FY18Q3 FY19Q3 FY20Q3 FY21Q3 FY22Q3 FY23Q3 FY24Q3 FY25Q2 FY26

CASH & CAPITAL

where the money actually goes5 CHARTS

FREE CASH FLOW

$0.4B
+204%
LATEST · Q2 FY26
0.4BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

STOCK-BASED COMP

$0.1B
+195%
LATEST · Q2 FY26
0.1BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

CAPITAL EXPENDITURE

$0.0B
+660%
LATEST · Q2 FY26
0.0BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

SHARES OUTSTANDING

0.07B
+12%
LATEST · Q2 FY26
0.07BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

DIVIDEND / SHARE

LATEST · Q2 FY26
Q3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

BALANCE SHEET

how much cushion there is3 CHARTS

CASH & EQUIVALENTS

$1.6B
+342%
LATEST · Q2 FY26
1.6BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

TOTAL DEBT

$4.4B
+99%
LATEST · Q2 FY26
4.4BQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26

DEBT / EBITDA (TTM)

4.5x
+13%
LATEST · Q2 FY26
4.5xQ3 FY16Q3 FY18Q3 FY20Q3 FY22Q3 FY24Q2 FY26
2.2x261.7x

OWNERSHIP

10 LARGEST HOLDERS · WHO OWNS THE FLOAT
INSTITUTIONS 105.04%INSIDERS 2.96%OTHER / RETAIL 0.00%851 INSTITUTIONAL FILERS
HOLDER% HELDSHARESVALUECHANGE
Blackrock Inc.8.61%5.6M$1.43B+2.6%
Vanguard Portfolio Management LLC4.60%3.0M$765.4MNEW
Capital World Investors4.12%2.7M$685.9M+0.3%
Vanguard Capital Management LLC4.08%2.6M$679.5MNEW
FMR, LLC3.51%2.3M$583.9M+184.1%
LSV Asset Management3.50%2.3M$583.7M-4.7%
Franklin Resources, Inc.3.02%2.0M$502.6M+7.7%
Dimensional Fund Advisors LP2.92%1.9M$486.2M-27.8%
State Street Corporation2.91%1.9M$485.3M+2.9%
EcoR1 Capital, LLC2.63%1.7M$437.8M+0.0%
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.